GLP-1 Daily (diarioglp1.com) is a proprietary health-tech platform engineered and operated by PerformacIA, a Brazilian software technology corporation specializing in high-precision algorithms, operational intelligence, and structured adherence platforms for the metabolic health sector.
Operating Entity Corporate Information
- Legal Entity: PERFORMACIA DESENVOLVIMENTO DE SOFTWARE NÃO CUSTOMIZÁVEL LTDA
- Trade Name: PerformacIA (d/b/a GLP-1 Daily)
- Tax ID: Brazilian Corporate Tax ID (CNPJ): 67.065.373/0001-11
- Corporate Status: Active & in Good Standing before the Federal Revenue of Brazil
- Headquarters: R. Visconde do Rio Branco, 1488, Suite 909, 9th Floor — Curitiba/PR, CEP: 80.420-210, Brazil
- Corporate Website: www.performacia.com.br
- Corporate Inquiries: contact@performacia.com.br
- Direct Patient Support: support@diarioglp1.com
- WhatsApp Helpdesk: +55 (55) 99968-2265
Clinical Purpose & Mission
Patients undergoing treatment with GLP-1 receptor agonists and dual GIP/GLP-1 agonists (such as semaglutide, tirzepatide, and liraglutide) face critical real-world adherence challenges: neglecting subcutaneous injection rotation (increasing lipohypertrophy risk), accelerated lean muscle loss (sarcopenia due to insufficient dietary protein), and lack of organized records to present to their treating physician.
GLP-1 Daily was created to resolve this gap: delivering a verified, medically respectful, and privacy-first digital companion with transparent mathematical modeling and clear institutional accountability.